Clinical trials: Stage IV Melanoma
Melanoma
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
To determine the recommended Phase IIa dose (RP2D) of the triplet combination. To determine the safety and efficacy of the combination at the RP2D.
- Trial name
- NCT06683755
- Testing
- Nivolumab, Relatlimab, Ipilimumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Melanoma, Stage IV Melanoma
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
Phase II trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have metastatic malignant melanoma.
- Trial name
- NCT00026143
- Testing
- recombinant interleukin-12, recombinant interferon alfa, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma Stage III or IV, No Prior Chemotherapy
Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
Investigation of the metabolic activity of sorafenib and sorafenib plus dacarbazine on melanoma metastasis in patients with melanoma stage III or IV on the basis of PET/CT, LDH and S-100 evaluation.
- Trial name
- NCT00794235
- Testing
- Sorafenib (Nexavar), Dacarbazine (DTIC)
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University of Zurich
Melanoma, Non-small Cell Lung Cancer
Pembrolizumab-PET Imaging
This is a two center, single arm, investigator sponsored trial (IST) with the PET tracer 89Zr-pembrolizumab to evaluate in vivo whole body distribution of 89Zr-Pembrolizumab in a registered indication: locally advanced metastatic…
- Trial name
- NCT02760225
- Testing
- 89Zr-Pembrolizumab, 89Zr-Pembrolizumab PET
- Where
- 2 sites in Netherlands
- Volunteers
- 18 people
- Sponsor
- University Medical Center Groningen
Melanoma
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
This is a multi-cohort, dose-escalation study of XL888 with a fixed dose of vemurafenib. New dose escalation or de-escalation cohorts will be assigned by the Principal Investigator (PI) with discussion with appropriate…
- Trial name
- NCT01657591
- Testing
- XL888, Vemurafenib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin)
Irofulven in Treating Patients With Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have stage IV…
- Trial name
- NCT00005968
- Testing
- irofulven
- Where
- 5 sites in United States
- Sponsor
- University of Colorado, Denver
Recurrent Metastatic Melanoma, Cutaneous Melanoma
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
The purpose of this study is to evaluate how effective Olaparib is when given as a treatment for primary or recurrent, unresectable or metastatic melanoma. This research study involves targeted therapy.
- Conditions
- Recurrent Metastatic Melanoma, Cutaneous Melanoma, Mucosal Melanoma, Uveal Melanoma
- Trial name
- NCT05482074
- Testing
- Olaparib
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Melanoma
Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma
To determine the efficacy as measured by objective tumor response of first-line treatment of metastatic melanoma with bevacizumab monotherapy
- Trial name
- NCT00139360
- Testing
- Bevacizumab
- Where
- Norway
- Volunteers
- 35 people
- Sponsor
- Haukeland University Hospital
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
This pilot phase I trial studies how well VX15/2503 (pepinemab) with or without ipilimumab and/or nivolumab work in treating participants with stage IIIB-D melanoma that can be removed by surgery.
- Conditions
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Trial name
- NCT03769155
- Testing
- Ipilimumab, Nivolumab, VX15/2503
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Emory University
Kidney Cancer, Melanoma (Skin)
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276835
- Testing
- High-dose interleukin-2, genistein
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Metastatic Melanoma
Immune Monitoring in Metastatic Melanoma
The mean survival time in the advanced tumor stage in the presence of distant metastases in malignant melanoma was less than 9 months until a few years ago.
- Trial name
- NCT04158544
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Regensburg
Metastatic Melanoma, CNS Metastases
Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls
This study has two ultimate goals: 1. Understand how the original melanoma from the skin spreads to the CNS. In order to study this we need to collect (and compare) the original skin melanoma, the CNS melanoma, as well as any…
- Trial name
- NCT01312506
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Recurrent Melanoma, Stage III Melanoma
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
Phase II trial to study the effectiveness of combining imatinib mesylate with bevacizumab in treating patients who have advanced melanoma or other metastatic or unresectable cancer.
- Conditions
- Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00074308
- Testing
- imatinib mesylate, bevacizumab, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
This randomized phase II trial studies how well trametinib with or without Akt inhibitor GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to other parts of the body (metastatic).
- Trial name
- NCT01979523
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Trametinib
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic uveal melanoma and…
- Trial name
- NCT04109456
- Testing
- IN10018, Cobimetinib, Atezolizumab
- Where
- 8 sites in United States, Australia
- Volunteers
- 51 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Melanoma
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
The objectives of this study are to determine the safety and activity profile of multiple doses of MDX-010, and to determine the whether the addition of cytotoxic chemotherapy (decarbazine [DTIC]) can augment the effects of…
- Trial name
- NCT00050102
- Testing
- MDX-010 (CTLA-4)
- Where
- 9 sites in United States
- Sponsor
- Bristol-Myers Squibb
Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
This randomized phase II trial studies how well cabozantinib-s-malate works compared with temozolomide or dacarbazine in treating patients with melanoma of the eye (ocular melanoma) that has spread to other parts of the body and…
- Conditions
- Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7
- Trial name
- NCT01835145
- Testing
- Cabozantinib S-malate, Dacarbazine, Laboratory Biomarker Analysis
- Where
- 228 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo +…
- Trial name
- NCT02908672
- Testing
- Atezolizumab, Cobimetinib, Vemurafenib
- Where
- 110 sites in United States, Australia and 18 more
- Volunteers
- 514 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
This is an open-label, dose-escalation study to determine the safety, maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of 188Re-PTI-6D2 in patients with metastatic melanoma.
- Trial name
- NCT00734188
- Testing
- PTI-6D2
- Where
- Israel
- Volunteers
- 21 people
- Sponsor
- Pain Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.